Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech and PRA Split Their China Clinical Stage JV

publication date: Dec 9, 2015
WuXi PharmaTech has split in two its clinical-stage China CRO joint venture with PRA Health Sciences of North Carolina. WuXi will take over control of the CRO's China operations, bringing them entirely in-house, and PRA will own the Hong Kong business. The two companies joined forces in 2013. PRA, a global CRO, added its China-based staff and global technology capabilities, including data capture, trial management and other IT systems. The current "restructuring," as it is being called, came at the request of WuXi. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital